Agios Pharmaceuticals, Inc. (FRA:8AP)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.35B -10.7% |
| Revenue (ttm) | 57.28M +78.3% |
| Net Income | -366.52M |
| EPS | -6.29 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 22.60 |
| Previous Close | 23.60 |
| Day's Range | 22.60 - 22.60 |
| 52-Week Range | 19.70 - 38.80 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company’s PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of a... [Read more]
News
Agios Pharmaceuticals Transcript: Status update
Announced a global license for cevidoplenib, a next-gen SYK inhibitor for ITP, with a capital-efficient deal structure and strong commercial synergies. Phase II data show durable efficacy and favorable safety, supporting phase III initiation in 2028.
Agios Pharmaceuticals Slides: Status update
Agios Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
Agios Pharmaceuticals Press release: Status update
Agios Pharmaceuticals issued a press release on June 1, 2026, disclosing material business information to investors.
Agios Pharmaceuticals enters license pact with Oscotec to develop cevidoplenib
Agios Pharmaceuticals (AGIO) announced an agreement with Oscotec, headquartered in South Korea, to license the exclusive global rights to cevidoplenib, an oral spleen tyrosine kinase inhibitor. Agios ...
Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib
Agios obtains exclusive global rights to novel, late-stage, next-generation, oral SYK inhibitor Agreement diversifies Agios' rare hematology portfolio with expansion into immune thrombocytopenia, unlo...
Agios Pharmaceuticals price target lowered to $40 from $41 at BofA
BofA lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $40 from $41 and keeps a Buy rating on the shares after the company announced tebapivat will not advance…
Agios scraps blood cancer drug program after study miss
Agios Pharmaceuticals said on Friday it will stop developing its experimental drug for a form of blood cancer after a mid-stage trial failed to show enough benefit.
Agios will not advance tebapivat in lower-risk myelodysplastic syndromes
Agios Pharmaceuticals (AGIO) announced that it will not advance tebapivat, a next-generation oral pyruvate kinase activator, in lower-risk myelodysplastic syndromes. This decision follows results from...
Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes
Results did not meet predefined threshold to support further development in LR-MDS Tebapivat was well tolerated, with no new safety signals observed CAMBRIDGE, Mass., May 29, 2026 (GLOBE NEWSWIRE) -- ...
Agios announces EC grants marketing authorization for PYRUKYND
Agios Pharmaceuticals (AGIO) announced that the European Commission has granted marketing authorization for PYRUKYND, an oral pyruvate kinase activator, in adults for the treatment of anemia associate...
Avanzanite Bioscience's Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia
AMSTERDAM--(BUSINESS WIRE)-- #Avanzanite--Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its par...
Agios' PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia
PYRUKYND is the only medicine approved in the EU for adults with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia Mitapivat is now approved for thalassemia in the U.S., S...
Agios Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026
The team reported a strong start to 2026, highlighted by the launch of AQVESME for thalassemia and the sNDA submission for mitapivat in sickle cell disease. Regulatory progress, robust clinical data, and a focus on rare hematology position the company for long-term value creation.
Agios Pharma submits sNDA to FDA for U.S. accelerated approval of mitapivat
Agios Pharmaceuticals (AGIO) announced the submission of its supplemental New Drug Application to the U.S. FDA for the U.S. accelerated approval of mitapivat, an oral pyruvate kinase activator, in sic...
Agios Pharmaceuticals to present mitapivat data at EHA Congress
Agios Pharmaceuticals (AGIO) announced that new data on mitapivat, an oral pyruvate kinase activator, will be featured in oral and poster presentations during the 31st European Hematology Association ...
Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease
sNDA submission follows agreement with FDA on confirmatory trial, a requirement of the accelerated approval pathway Confirmatory trial designed to demonstrate clinical benefit of mitapivat on reducing...
Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias
Detailed results from RISE UP Phase 3 trial of mitapivat in sickle cell disease selected for distinguished Plenary Abstracts Session Company to host investor conference call and webcast during EHA 202...
Agios Pharmaceuticals price target lowered to $36 from $39 at Truist
Truist lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $36 from $39 and keeps a Buy rating on the shares. The company’s Q1 earnings included a more rapid…
Agios Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw 138% revenue growth to $20.7M, driven by a strong AQVESME launch in thalassemia and robust U.S. demand. Mitapivat sNDA for sickle cell disease is on track for Q2, and the pipeline remains catalyst-rich with key data readouts expected this year.
Agios Pharmaceuticals Earnings release: Q1 2026
Agios Pharmaceuticals released its Q1 2026 earnings on April 29, 2026, summarizing the period's financial results.
Agios Pharmaceuticals Slides: Q1 2026
Agios Pharmaceuticals has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 29, 2026.
Agios Pharmaceuticals Quarterly report: Q1 2026
Agios Pharmaceuticals has published its Q1 2026 quarterly earnings report on April 29, 2026.
Agios Pharmaceuticals reports Q1 EPS ($1.69), consensus ($1.79)
Reports Q1 revenue $20.75M, consensus $13.65M. Reports Q1 Cash, cash equivalents, and marketable securities $1.045B. “Our Q1 performance reflects strong execution and significant progress against our ...
Agios Reports First Quarter 2026 Financial Results and Provides Business Update
Mitapivat (PYRUKYND® and AQVESME™) generated worldwide net revenues of $20.7 million in the first quarter of 2026, compared to $8.7 million in the first quarter of 2025 Strong initial U.S. commercial ...
Agios Pharmaceuticals Proxy statement: Proxy filing
Agios Pharmaceuticals filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.